All In Biotech

Free tool

FAERS Monitor: Apadaz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208653 or its brand name (Apadaz, Acetaminophen, Benzhydrocodone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

21

Serious

15

71% of reports

Hospitalization

7

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use5
  • product dose omission issue5
  • urinary tract infection4
  • fluid retention3
  • kidney infection3
  • localised infection3
  • peripheral swelling3
  • rash3
  • skin discomfort3
  • condition aggravated2
  • decreased appetite2
  • diarrhoea2
  • drug ineffective2
  • infection2
  • injection site pain2

Reports by year received

View as table
YearReports
20201
20212
20234
20245
20255
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin discomfortSignal31115.2390.92,316
kidney infectionSignal3153.253.7314
localised infectionSignal3124.343.6254
fluid retentionSignal359.120.7118
urinary tract infectionSignal423.59.766
peripheral swellingSignal319.56.836
product dose omission issueSignal517.07.961
infection213.83.713
decreased appetite28.62.37
rashSignal36.92.410
condition aggravated26.61.85
injection site pain26.51.75
off label useSignal55.72.716
diarrhoea23.10.81
drug ineffective21.50.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.